Sellas Life Sciences: Wellington Adds Shares While Two Law Firms Circle the GPS Study
Published on 09/17/2026 at 05:41 | Editorial boerse-global.de
Two opposing forces are pulling at Sellas Life Sciences right now, and the market is struggling to decide which one matters more. On one side, an institutional heavyweight went bargain hunting. On the other, a pair of US law firms are probing how the company communicated a key milestone in its flagship trial.
Wellington Management Group disclosed on 10 September that it had added to its position in the biopharmaceutical company, according to a mandatory filing. The notice gave no specifics on the size of the stake or the voting rights attached to it. Shares changed hands at EUR 9.86 on the day, a modest gain of 0.8%.
The 80th Death That Triggered Everything
The legal scrutiny centres on Galinpepimut-S, or GPS, Sellas' lead product candidate, which is being tested in a Phase 3 trial. Reports indicate the study reached its pre-specified 80th death event — the trigger point for releasing topline results — without Sellas having published those results.
Pomerantz LLP, a firm specialising in securities law, is investigating possible violations and has invited affected shareholders to come forward regarding potential civil claims of alleged securities fraud. No regulatory body has made any finding of actual misconduct by management. Separately, Bronstein, Gewirtz & Grossman is reviewing whether claims may exist for purchasers of the stock, a step that is early and frequently inconsequential under US law.
When the milestone news broke, the shares fell USD 2.00, or 13.15%, to USD 13.21 that day. The data itself had not yet been released at that point.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
That gap — an event count crossing a threshold while the underlying results remain unpublished — sits at the heart of the questions now being raised. Investors are asking, reasonably enough, whether the market was adequately informed about the trial's true risk profile before that threshold was crossed. Still, an investigation is not a lawsuit, and a lawsuit is not a verdict.
A Stock That Has Already Priced In Plenty of Doubt
The trading record shows just how much pressure the equity has absorbed. It now trades roughly 33% below its 52-week high of EUR 15.25. Set against that, the shares are still up 258% over the course of the year — a spread that captures how violently this name swings between euphoria and disillusionment.
That distance from the peak suggests the market has already discounted some of the uncertainty surrounding GPS, even before the actual study readout lands. What is being traded here is an expectation, not a fact. The 80th death is a procedural event in the trial; it is not evidence that the drug's safety profile is any better or worse than it was before the milestone. Yet the share price reaction, and now the law firms' interest, implies that many participants are reading it as a warning rather than a neutral step in the process.
A Second Program Steps Into the Spotlight
Away from the turmoil around the main study, Sellas is preparing to present scientific work on its second development project. At this year's AACR conference on pancreatic cancer, the company will showcase three research papers on SLS009, also known as Tambiciclib, through poster presentations.
The candidate is a selective CDK9 inhibitor. The work being presented is based on preclinical models of ductal adenocarcinoma of the pancreas, including variants carrying KRAS mutations — targeting some of the hardest-to-treat forms of the disease.
What to Watch From Here
Collective-action investigations are hardly rare in biotech, and the situation around Sellas fits a broader pattern of similar cases at other drug developers whose trials have recently stumbled. That context softens the news somewhat without rendering it meaningless. For a company whose valuation leans heavily on a single trial programme, any uncertainty around communication and transparency carries outsized weight.
The coming days bring decisions on several fronts at once. On one hand, there is the question of whether the preclinical SLS009 data can live up to expectations. On the other, market participants want clarity on where the advanced GPS trial stands so they can gauge the legal exposure.
Despite the recent headwinds, the stock remains up 248% since the start of the year. No fresh analyst assessments have been issued in the past two weeks. For anyone holding this name, the Phase 3 results and the progress of the legal review are the two catalysts that matter — together they will determine whether the market's current scepticism turns out to have been overdone or entirely justified.
Ad
Sellas Life Sciences Stock: New Analysis - 17 September
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
